Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): Distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea

Leukemia

Volumn 16, Issue 10, 2002, Pages 2078-2083

  Bernasconi, P ^a   Boni, M ^a   Caviglianio, P M ^a   Calatroni, S ^a   Brusamolino, E ^a   Passamonti, F ^a   Volpe, G ^b   Pistorio, A ^c   Giardini, I ^a   Rocca, B ^a   Caresana, M ^a   Lazzarino, M ^a   Bernasconi, C ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

17p; Chromosome abnormalities; Cytogenetics; FISH; TP53

Indexed keywords

HYDROXYUREA; PIPOBROMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHROMOSOME 1; CHROMOSOME 17; CHROMOSOME 7Q; CHROMOSOME ABERRATION; CHROMOSOME ARM; CHROMOSOME DELETION; CONTROLLED STUDY; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; GENE MUTATION; HUMAN; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SURVIVAL; THROMBOCYTHEMIA; THROMBOCYTOSIS; TRISOMY;

EID: 0036797010     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402638     Document Type: Article

References (36)

1. Nimer SD. Essential thrombocythemia: another heterogeneous disease better understood? Blood 1999; 93: 415-416.
2. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodighiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythaemia. J Clin Oncol 1990; 8: 556-562.
3. Finazzi G, Ruggeri M, Rodighiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000; 110: 577-583.
4. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodighiero F, Barbui T. Hydroxyurea in the treatment of patients with essential thrombocythaemia at high risk of thrombosis: a prospective randomized trial. N Engl J Med 1995; 332: 1132-1136.
5. Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991; 85: 124-127.
6. Chistolini A, Mazzucconi MG, Ferrari A, La Verde G, Ferrazza G, Dragoni F, Vitale A, Arcieri R, Mandelli F. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica 1990; 75: 537-540.
7. Van de Pette JEW, Prochazka AV, Pearson TC, Singh AK, Dickson ER, Wetherley-Mein G. Primary thrombocythaemia treated with busulfan. Br J Haematol 1986 62: 229-237.
8. Sterkers Y, Preudhomme C, Laï J-L, Demory J-L, Caulier M-T, Wattel E, Bordessoule D, Bauters F, Fenaux P. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91: 616-622.
9. Messora C, Bensi L, Vanzanelli P, Temperani P, Carotenuto M, Sacchi S. Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman. Haematologica 1996; 81: 51-53.
10. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the polycythemia vera study group with essential thrombocythaemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
11. ISCN (1995) Mitelman F (ed). An International System for Human Cytogenetic Nomenclature. S Karger: Basel, 1995.
12. Bernasconi P, Astori C, Cavigliano PM, Boni M, Malcovati L, Calatroni S, Caresana M, Bernasconi C. Cytogenetic and FISH analyses in five patients with hypoplastic bone marrow. Leukemia 2000; 14: 1322-1323.
13. Saglio G, Guerrasio A, Tassinari A, Ponzetto A, Zaccaria A, Testoni P, Celso B, Rege-Cambrin G, Serra A, Pegoraro L, Avanzi GC, Attadia V, Falda M, Gavosto F. Variability of the molecular defects corresponding to the presence of a Philadelphia chromosome in human hematologic malignancies. Blood 1988; 72: 1203-1208.
14. Gaidano G, Pastore C, Santini V, Nomdedeu J, Gamberi B, Capello D, Vischia F, Resegotti L, Mazza U, Rossi Ferrini P, Lo Coco F, Saglio F. Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. Genes Chromosomes Cancer 1997; 19: 250-255.
15. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991; 88: 5413-5417.
16. Fenaux P, Simon M, Caulier MT, Lax JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549-556.
17. Sessarego M, Defferrari R, Dejana AM, Rebuttato AM, Fugazza G, Salvidio E, Ajmar F. Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12 years study. Cancer Genet Cytogenet 1989; 43: 57-65.
18. Liozon E, Brigadeau C, Trimoreau F, Desangles F, Fermeaux V, Praloran V, Bordessoule D. Is treatment with hydroxyurea leukemogenic in essential thrombocythemia? An analysis of three new cases of leukemic transformation and review of the literature. Hematol Cell Ther 1997; 39: 11-18.
19. Liu T-C, Suri R. Multiple factors in the transformation of essential thrombocythemia to acute leukemia or myelodysplastic syndrome. Blood 1998; 92: 1465-1466.
20. Soenen V, Preudhomme C, Roumier C, Daudignon A, Laï JL, Fenaux P. 17p deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 1998; 91: 1008-1015.
21. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletions or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001; 19: 1405-1413.
22. Castro PD, Liang JC, Nagarajan L. Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. Blood 2000; 95: 2138-2143.
23. Merlat A, Laï JL, Sterkers Y, Demory JL, Bauters F, Preudhomme C, Fenaux P. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia 1999; 13: 250-257.
24. Hernadez J-A, Florensa L, Solè F, Bosch M-A, Espinet B. Acute myeloid leukemia with 17p abnormality in untreated essential thrombocythemia. Leukemia 2001; 15: 1308.
25. Brusamolino E, Canevari A, Salvaneschi L, Merante S, Bernasconi C. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients. Cancer Treat Rep 1984; 68: 1339-1342.
26. Brusamolino E, Salvaneschi L, Canevari A, Bernasconi C. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia. J Clin Oncol 1984; 2: 558-561.
27. Passamonti F, Brusamolino E, Lazzarino M, Barate C, Klersy C, Orlandi E, Canevari A, Castelli G, Merante S, Bernasconi C. Efficacy of pipobroman in the treatment of polycythemia vera: longterm results in 163 patients. Haematologica 2000; 85: 1011-1018.
28. Kibbelaar RE, Mulder JW, van Kamp H, Dreef EJ, Wessels HW, Beverstock GC, Haak HL, Raap AK, Kluin PM. Nonradioactive in situ hybridisation of the translocation t(1;7) in myeloid malignancies. Genes Chromosomes Cancer 1992; 4: 128-134.
29. Anderson MK, Pedersen-Bjergaard J. increased frequency of dicentric chromosomes in therapy-related MDS and AML compared to de novo disease is significantly related to previous treatment with alkylating agents and suggests a specific susceptibility to chromosome breakage at the centromere. Leukemia 2000; 14: 105-110.
30. Pedersen B. Survival of patients with t(1;7)(p11;p11). Report of two cases and review of the literature. Cancer Genet Cytogenet 1992; 60: 53-59.
31. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li C-Y, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 113: 763-771.
32. Hayashi S, Iwama H, Uchida Y, Kawakubo K, Inatomi Y, Nagasu M, Miyazawa K, Ohyashiki JH, Toyama K. Essential thrombocythemia in transformation to acute leukemia (FAB-M0) as a natural history from myelofibrosis with t(1;7). Rinsho Ketsueki 1997; 38: 445-447.
33. Shibata K, Shimamoto Y, Suga K, Sano M, Matsuzaki M, Yamaguchi M. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation - a brief review of recent literature. Acta Haematol 1994; 91: 84-88.
34. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc 2001; 76: 22-28.
35. Najean Y, Rain JD for the French Polycythemia Study Group Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90, 3370-3379.
36. Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leuk Lymphoma 2000; 37: 379-385.